Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jid.2016.10.036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma.
Semin Hematol
October 2024
Multiple Myeloma Center of Excellence, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York NY USA; The Multiple Myeloma Research Foundation, Norwalk, CT. Electronic address:
Melanoma Antigen Genes (MAGE) are expressed in a broad range of cancers, including multiple myeloma. MAGE have been under investigation for more than 3 decades as targets for immune therapy, while in parallel, interrogation of their functions has revealed activities that may be particularly critical in multiple myeloma. MAGE-C1 is expressed in about 75% of newly diagnosed cases and this is maintained through the natural history of the disease.
View Article and Find Full Text PDFDevelopment of Ligands and Degraders Targeting MAGE-A3.
J Am Chem Soc
September 2024
Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, Connecticut 06511, United States.
Type I melanoma antigen (MAGE) family members are detected in numerous tumor types, and expression is correlated with poor prognosis, high tumor grade, and increased metastasis. Type I MAGE proteins are typically restricted to reproductive tissues, but expression can recur during tumorigenesis. Several biochemical functions have been elucidated for them, and notably, MAGEs regulate proteostasis by serving as substrate recognition modules for E3 ligase complexes.
View Article and Find Full Text PDFGene and Protein Expression of MAGE and Associated Immune Landscape Elements in Non-Small-Cell Lung Carcinoma and Urothelial Carcinomas.
J Immunother
October 2024
Institute of Urologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Article Synopsis
- MAGE-A is a cancer-associated antigen expressed in various tumors but has limited presence in normal tissues; this study focused on its expression in urinary bladder and lung cancers while evaluating the immune environment.
- The researchers analyzed MAGE-A and PD-L1 levels in tumor samples using immunohistochemistry and RNA sequencing, finding that 57% of samples showed detectable MAGE-A expression, with no significant difference between the two cancer types.
- Treatment with checkpoint inhibitors did not alter MAGE-A expression or other immune markers in urothelial carcinoma, suggesting that previous tumor samples can still be useful for evaluating MAGE-targeted treatments.
Cancer/testis antigen expression and co-expression patterns in gastroesophageal adenocarcinoma.
Med Oncol
August 2024
Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14206, USA.
Gastroesophageal adenocarcinoma (GEAC) poses a significant challenge due to its poor prognosis and limited treatment options. Recently, Cancer/testis antigens (CTAs) have emerged as potential therapy targets due to their high expression in tumor cells and their immunogenic nature. We aimed to explore the expression and co-expression of CTAs in GEAC.
View Article and Find Full Text PDFGastroesophageal adenocarcinoma (GEAC) poses a significant challenge due to its poor prognosis and limited treatment options. Recently, Cancer/testis antigens (CTAs) have emerged as potential therapy targets due to their high expression in tumor cells and their immunogenic nature. We aimed to explore the expression and co-expression of CTAs in GEAC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!